Comment on “Tumor-initiating cells establish an IL-33–TGF-β niche signaling loop to promote cancer progression”

Author:

Kamphuis Jasper B. J.1ORCID,Worrall William P. M.1ORCID,Stackowicz Julien23,Mougel Aurélie1ORCID,Mauré Emilie1ORCID,Conde Eva23ORCID,Bruhns Pierre2ORCID,Guilleminault Laurent14ORCID,Gaudenzio Nicolas5ORCID,Chen Jinmiao6ORCID,Gentek Rebecca7ORCID,Reber Laurent L.12ORCID

Affiliation:

1. Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM U1291, University of Toulouse, CNRS U5282, 31024 Toulouse, France.

2. Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, 75015 Paris, France.

3. Sorbonne Université, 75006 Paris, France.

4. Department of Respiratory Medicine, Toulouse University Hospital, Faculty of Medicine, 31059 Toulouse, France.

5. Unité de Différenciation Epithéliale et Autoimmunité Rhumatoïde (UDEAR), UMR 1056, INSERM, Université de Toulouse, 31059 Toulouse, France.

6. Singapore Immunology Network, Agency for Science, Technology and Research, 138648 Singapore.

7. Centre for Inflammation Research, University of Edinburgh, EH16 4TJ Edinburgh, UK.

Abstract

Taniguchi et al . (Research Articles, 17 July 2020, p. 269) claim that the cytokine interleukin-33 induces accumulation of tumor-associated macrophages expressing the immunoglobulin E receptor FcεRI. Although these findings hold great therapeutic promise, we provide evidence that the anti-FcεRI antibody used in this study is not specific for FcεRI on macrophages, which raises concerns about the validity of some of the conclusions.

Funder

Kennedy Trust for Rheumatology Research

European Research Council

Institut national de la santé et de la recherche médicale

Institut Pasteur

Société Française de Dermatologie et de Pathologie Sexuellement Transmissible

Société Française d’Allergologie

Marie Skłodowska-Curie individual fellowship

Chancellor’s Fellowship of the University of Edinburgh

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3